XtalPi Holdings (2228) H1 2025 earnings summary

Executive summary

• Revenue for 1H25 surged 403.8% year-over-year to RMB517.1 million, marking the first half-year profitability, driven by major drug discovery collaborations and robotics solutions.

• Adjusted net profit reached RMB141.6 million, compared to an adjusted net loss of RMB251.4 million in the prior year; net profit was RMB75.6 million, reversing a RMB1,237.6 million loss.

• Cash balance stood at RMB5,307.7 million as of June 30, 2025, with a 20% reduction in average monthly cash burn to RMB49.7 million, supporting operations for approximately 8.9 years.

• Included in the MSCI China Small Cap Index, reflecting international capital market recognition.

• Major strategic collaborations, technological advancements in AI and robotics, and new platform launches drove business growth and industry recognition.

Financial highlights

• Drug discovery solutions revenue surged 615.2% year-over-year to RMB435.2 million, mainly due to a US$51 million milestone from DoveTree collaboration.

• Intelligent robotics solutions revenue grew 95.9% to RMB81.9 million, driven by automated chemical synthesis and global R&D contracts.

• R&D expenses rose 5.3% year-over-year to RMB221.5 million.

• Operating profit reached RMB32.7 million, reversing a RMB392.9 million loss in the prior year.

• Cash balance increased 70% to RMB5,307.7 million, mainly due to new share placements.

Outlook and guidance

• Management expects continued growth in drug discovery and robotics solutions, leveraging AI, quantum physics, and automation, with a focus on expanding global collaborations and commercializing new platforms.

• Sufficient working capital and strong cash reserves support long-term strategy and expansion.